Skip to main content
Filiz Sen, MD, Pathology, New York, NY

FilizSenMD

Pathology New York, NY

Hematopathology, Anatomic Pathology, Clinical Pathology

Associate Professor, Pathology and Laboratory Medicine, Hofstra North Shore-LIJ

Dr. Sen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Sen's full profile

Already have an account?

  • Office

    1275 York Avenue
    New York, NY 10065

Education & Training

  • Duke University Hospital
    Duke University HospitalResidency, Pathology-Anatomic and Clinical, 1998 - 2002
  • Montefiore Medical Center/Albert Einstein College of Medicine
    Montefiore Medical Center/Albert Einstein College of MedicineResidency, Pathology-Anatomic and Clinical, 1995 - 1998
  • Marmara Univ- Fac Med
    Marmara Univ- Fac MedClass of 1990

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 2002 - Present
  • NJ State Medical License
    NJ State Medical License 2021 - 2025
  • NY State Medical License
    NY State Medical License 2002 - 2025
  • NC State Medical License
    NC State Medical License 2004 - 2006
  • American Board of Pathology Anatomic Pathology & Clinical Pathology
  • American Board of Pathology Hematology

Publications & Presentations

PubMed

Abstracts/Posters

  • Dual Driver Mutant BCR-ABL1-Negative Myeloid Neoplasms: Multicenter Clinicopathologic and Genomic Analysis
    Filiz Sen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Leukemia Cell of Origin Influences p53 Activity and Therapeutic Sensitivity Via an Evi1-Dependent Mechanism
    Filiz Sen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

  • Selinexor, a First-in-Class XPO1 Inhibitor, Is Efficacious and Tolerable in Patients with Myelodysplastic Syndromes Refractory to Hypomethylating Agents 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018